AMRN Latest News

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

globenewswire.com — Apr 15, 2026

DUBLIN and BRIDGEWATER, N. J.

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

fool.com — Mar 7, 2026

Amarin has one drug, and it has lost key patent protections. The company is cutting costs in an effort to generate positive cash flow.

AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know

zacks.com — Mar 5, 2026

Amarin shares surge 37. 7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.

Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now

fool.com — Mar 3, 2026

Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth pr

Amarin Q4 Earnings Call Highlights

defenseworld.net — Feb 28, 2026

Amarin (NASDAQ: AMRN) executives told investors that 2025 marked a "substantial achievement" year as the company advanced a strategic pivot toward a m